Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 11 |
| List of Tables | 10 | 2 |
| List of Figures | 12 | 1 |
| Introduction | 13 | 1 |
| Global Markets Direct Report Coverage | 13 | 1 |
| Metastatic Renal Cell Carcinoma Overview | 14 | 1 |
| Therapeutics Development | 15 | 2 |
| Pipeline Products for Metastatic Renal Cell Carcinoma Overview | 15 | 1 |
| Pipeline Products for Metastatic Renal Cell Carcinoma Comparative Analysis | 16 | 1 |
| Metastatic Renal Cell Carcinoma Therapeutics under Development by Companies | 17 | 4 |
| Metastatic Renal Cell Carcinoma Therapeutics under Investigation by Universities/Institutes | 21 | 1 |
| Metastatic Renal Cell Carcinoma Pipeline Products Glance | 22 | 4 |
| Late Stage Products | 22 | 1 |
| Clinical Stage Products | 23 | 1 |
| Early Stage Products | 24 | 1 |
| Unknown Stage Products | 25 | 1 |
| Metastatic Renal Cell Carcinoma Products under Development by Companies | 26 | 3 |
| Metastatic Renal Cell Carcinoma Products under Investigation by Universities/Institutes | 29 | 1 |
| Metastatic Renal Cell Carcinoma Companies Involved in Therapeutics Development | 30 | 44 |
| Acceleron Pharma, Inc. | 30 | 1 |
| Amgen Inc. | 31 | 1 |
| Argos Therapeutics, Inc. | 32 | 1 |
| Astellas Pharma Inc. | 33 | 1 |
| Bayer AG | 34 | 1 |
| Bionomics Limited | 35 | 1 |
| Bionovis SA | 36 | 1 |
| Bristol-Myers Squibb Company | 37 | 1 |
| Cellceutix Corporation | 38 | 1 |
| Celldex Therapeutics, Inc. | 39 | 1 |
| Cerulean Pharma, Inc. | 40 | 1 |
| Dr. Reddy's Laboratories Limited | 41 | 1 |
| EirGenix Inc. | 42 | 1 |
| Eisai Co., Ltd. | 43 | 1 |
| Eli Lilly and Company | 44 | 1 |
| Exelixis, Inc. | 45 | 1 |
| Gene Techno Science Co., Ltd. | 46 | 1 |
| Genor BioPharma Co., Ltd. | 47 | 1 |
| Immune Design Corp. | 48 | 1 |
| Immunicum AB | 49 | 1 |
| Incyte Corporation | 50 | 1 |
| Mabion SA | 51 | 1 |
| MedImmune, LLC | 52 | 1 |
| Merck &Co., Inc. | 53 | 1 |
| Merck KGaA | 54 | 1 |
| Millennium Pharmaceuticals Inc | 55 | 1 |
| Mycenax Biotech Inc. | 56 | 1 |
| NewLink Genetics Corporation | 57 | 1 |
| Novartis AG | 58 | 1 |
| Oncobiologics, Inc. | 59 | 1 |
| Ono Pharmaceutical Co., Ltd. | 60 | 1 |
| Panacea Biotec Limited | 61 | 1 |
| Peloton Therapeutics, Inc. | 62 | 1 |
| Pfizer Inc. | 63 | 1 |
| Prima BioMed Ltd. | 64 | 1 |
| Rexahn Pharmaceuticals, Inc. | 65 | 1 |
| Richter Gedeon Nyrt. | 66 | 1 |
| Seattle Genetics, Inc. | 67 | 1 |
| Sevion Therapeutics, Inc. | 68 | 1 |
| Syndax Pharmaceuticals Inc | 69 | 1 |
| Taiwan Liposome Company, Ltd. | 70 | 1 |
| Tocagen Inc. | 71 | 1 |
| TVAX Biomedical, Inc. | 72 | 1 |
| Tyrogenex, Inc. | 73 | 1 |
| Metastatic Renal Cell Carcinoma Therapeutics Assessment | 74 | 22 |
| Assessment by Monotherapy Products | 74 | 1 |
| Assessment by Combination Products | 75 | 1 |
| Assessment by Target | 76 | 8 |
| Assessment by Mechanism of Action | 84 | 7 |
| Assessment by Route of Administration | 91 | 2 |
| Assessment by Molecule Type | 93 | 3 |
| Drug Profiles | 96 | 257 |
| AGS-16C3F Drug Profile | 96 | 1 |
| avelumab Drug Profile | 97 | 5 |
| bevacizumab biosimilar Drug Profile | 102 | 2 |
| bevacizumab biosimilar Drug Profile | 104 | 1 |
| bevacizumab biosimilar Drug Profile | 105 | 1 |
| bevacizumab biosimilar Drug Profile | 106 | 1 |
| bevacizumab biosimilar Drug Profile | 107 | 1 |
| bevacizumab biosimilar Drug Profile | 108 | 1 |
| bevacizumab biosimilar Drug Profile | 109 | 1 |
| bevacizumab biosimilar Drug Profile | 110 | 1 |
| bevacizumab biosimilar Drug Profile | 111 | 1 |
| bevacizumab biosimilar Drug Profile | 112 | 1 |
| bevacizumab biosimilar Drug Profile | 113 | 1 |
| BNC-105 Drug Profile | 114 | 5 |
| cabozantinib s-malate Drug Profile | 119 | 18 |
| capmatinib Drug Profile | 137 | 3 |
| CDX-014 Drug Profile | 140 | 1 |
| Cellular Immunotherapy for Metastatic Renal Cell Carcinoma Drug Profile | 141 | 1 |
| Cellular Immunotherapy for Metastatic Renal Cell Carcinoma and Melanoma Drug Profile | 142 | 1 |
| crizotinib Drug Profile | 143 | 7 |
| CRLX-101 Drug Profile | 150 | 11 |
| dalantercept Drug Profile | 161 | 4 |
| durvalumab Drug Profile | 165 | 10 |
| emibetuzumab Drug Profile | 175 | 2 |
| entinostat Drug Profile | 177 | 7 |
| flucytosine ER + vocimagene amiretrorepvec Drug Profile | 184 | 7 |
| G-305 Drug Profile | 191 | 2 |
| IMP-321 Drug Profile | 193 | 4 |
| INCAGN-1876 Drug Profile | 197 | 2 |
| Intuvax Drug Profile | 199 | 6 |
| ipilimumab Drug Profile | 205 | 8 |
| KM-3174 Drug Profile | 213 | 11 |
| lenvatinib mesylate Drug Profile | 224 | 11 |
| LY-2510924 Drug Profile | 235 | 2 |
| Monoclonal Antibody Conjugate to Target G250 Antigen for Renal Cell Carcinoma Drug Profile | 237 | 1 |
| nivolumab Drug Profile | 238 | 28 |
| Orellanine Drug Profile | 266 | 1 |
| panobinostat Drug Profile | 267 | 8 |
| pazopanib hydrochloride + pembrolizumab Drug Profile | 275 | 1 |
| pembrolizumab Drug Profile | 276 | 31 |
| PT-2385 Drug Profile | 307 | 2 |
| radium Ra 223 dichloride Drug Profile | 309 | 9 |
| Recombinant Protein for Oncology Drug Profile | 318 | 1 |
| rocapuldencel-T Drug Profile | 319 | 6 |
| RX-0201 Drug Profile | 325 | 4 |
| sapanisertib Drug Profile | 329 | 3 |
| SGN-CD70A Drug Profile | 332 | 1 |
| Small Molecules to Inhibit SCD1 for Metastatic Renal Cell Carcinoma Drug Profile | 333 | 1 |
| SNX-5422 Drug Profile | 334 | 2 |
| SVN-002 Drug Profile | 336 | 1 |
| TLC-388 Drug Profile | 337 | 2 |
| trebananib Drug Profile | 339 | 4 |
| TVI-Kidney-1 Drug Profile | 343 | 1 |
| varlilumab Drug Profile | 344 | 6 |
| X-82 Drug Profile | 350 | 3 |
| Metastatic Renal Cell Carcinoma Dormant Projects | 353 | 5 |
| Metastatic Renal Cell Carcinoma Discontinued Products | 358 | 1 |
| Metastatic Renal Cell Carcinoma Product Development Milestones | 359 | 14 |
| Featured News &Press Releases | 359 | 1 |
| Jul 22, 2016: Immunicum Submits IND Application To The Food And Drug Administration For Approval To Treat Kidney Cancer Patients In The United States In Its Ongoing Phase II-Trial | 359 | 1 |
| Jun 13, 2016: Immunicum presents continued improvement in phase I/II survival data for INTUVAX treated renal cancer patients | 359 | 1 |
| Jun 13, 2016: Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 in Metastatic Renal Cell Carcinoma Following Interim Data Review | 360 | 1 |
| Jun 09, 2016: Cerulean Announces Manuscript Published in Annals of Oncology | 360 | 1 |
| Jun 06, 2016: Rexahn Pharmaceuticals Presents Clinical Data on Archexin at the 2016 ASCO Annual Meeting | 361 | 1 |
| May 24, 2016: Eisai To Present on Lenvima at 52nd Annual Meeting of the American Society of Clinical Oncology | 362 | 1 |
| Apr 25, 2016: Health Canada Approves OPDIVO (nivolumab) for the treatment of Advanced or Metastatic Renal Cell Carcinoma | 363 | 1 |
| Apr 20, 2016: Rexahn Pharmaceuticals Presents Clinical Trial Results for Archexin at the 2016 American Association for Cancer Research Annual Meeting | 364 | 2 |
| Jan 18, 2016: U.S. FDA Accepts For Priority Review sNDA For Eisai S Anticancer Agent Lenvatinib Seeking Approval For Renal Cell Carcinoma | 366 | 1 |
| Jan 11, 2016: Rexahn Pharmaceuticals Archexin Shows Dose-Dependent Tumor Reduction in a Phase IIa Clinical Study | 366 | 2 |
| Dec 10, 2015: Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 for Metastatic Renal Cell Carcinoma Following Second Planned Interim Analysis | 368 | 1 |
| Nov 23, 2015: FDA approves Opdivo to treat advanced form of kidney cancer | 368 | 1 |
| Nov 05, 2015: Rexahn Pharmaceuticals Reports Interim Clinical Data for Archexin at the 14th International Kidney Cancer Symposium | 369 | 2 |
| Oct 27, 2015: Cerulean Announces Poster Presentations at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | 371 | 1 |
| Oct 19, 2015: Phase II Trial Results on Novel Anticancer Agent Lenvima in Renal Cell Carcinoma Published in The Lancet Oncology | 371 | 2 |
| Appendix | 373 | 2 |
| Methodology | 373 | 1 |
| Coverage | 373 | 1 |
| Secondary Research | 373 | 1 |
| Primary Research | 373 | 1 |
| Expert Panel Validation | 373 | 1 |
| Contact Us | 373 | 1 |
| Disclaimer | 374 | 1 |